Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

被引:187
作者
Belcaid, Zineb [1 ]
Phallen, Jillian A. [1 ]
Zeng, Jing [2 ]
See, Alfred P. [1 ]
Mathios, Dimitrios [1 ]
Gottschalk, Chelsea [1 ]
Nicholas, Sarah [1 ]
Kellett, Meghan [1 ]
Ruzevick, Jacob [1 ]
Jackson, Christopher [1 ]
Albesiano, Emilia [3 ]
Durham, Nicholas M. [3 ]
Ye, Xiaobu [1 ]
Tran, Phuoc T. [2 ]
Tyler, Betty [1 ]
Wong, John W. [2 ]
Brem, Henry [1 ,4 ,5 ,6 ]
Pardoll, Drew M. [3 ]
Drake, Charles G. [3 ]
Lim, Michael [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Oncol & Med, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA
[6] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA
来源
PLOS ONE | 2014年 / 9卷 / 07期
关键词
MONOCLONAL-ANTIBODIES; ADJUVANT TEMOZOLOMIDE; IMMUNOTHERAPY; IPILIMUMAB; RADIOTHERAPY; MELANOMA; CONCOMITANT; GUIDANCE; IMMUNITY;
D O I
10.1371/journal.pone.0101764
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Glioblastoma (GBM) is the most common malignant brain tumor in adults and is associated with a poor prognosis. Cytotoxic T lymphocyte antigen-4 (CTLA-4) blocking antibodies have demonstrated an ability to generate robust antitumor immune responses against a variety of solid tumors. 4-1BB (CD137) is expressed by activated T lymphocytes and served as a co-stimulatory signal, which promotes cytotoxic function. Here, we evaluate a combination immunotherapy regimen involving 4-1BB activation, CTLA-4 blockade, and focal radiation therapy in an immune-competent intracranial GBM model. Methods: GL261-luciferace cells were stereotactically implanted in the striatum of C57BL/6 mice. Mice were treated with a triple therapy regimen consisted of 4-1BB agonist antibodies, CTLA-4 blocking antibodies, and focal radiation therapy using a small animal radiation research platform and mice were followed for survival. Numbers of brain-infiltrating lymphocytes were analyzed by FACS analysis. CD4 or CD8 depleting antibodies were administered to determine the relative contribution of T helper and cytotoxic T cells in this regimen. To evaluate the ability of this immunotherapy to generate an antigen-specific memory response, long-term survivors were re-challenged with GL261 glioma en B16 melanoma flank tumors. Results: Mice treated with triple therapy had increased survival compared to mice treated with focal radiation therapy and immunotherapy with 4-1BB activation and CTLA-4 blockade. Animals treated with triple therapy exhibited at least 50% long-term tumor free survival. Treatment with triple therapy resulted in a higher density of CD4(+) and CD8(+) tumor infiltrating lymphocytes. Mechanistically, depletion of CD4(+) T cells abrogated the antitumor efficacy of triple therapy, while depletion of CD8(+) T cells had no effect on the treatment response. Conclusion: Combination therapy with 4-1BB activation and CTLA-4 blockade in the setting of focal radiation therapy improves survival in an orthotopic mouse model of glioma by a CD4(+) T cell dependent mechanism and generates antigen-specific memory.
引用
收藏
页数:9
相关论文
共 34 条
[1]   Sequential Immunotherapy by Vaccination With GM-CSF-expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors [J].
Agarwalla, Pankaj ;
Barnard, Zachary ;
Fecci, Peter ;
Dranoff, Glenn ;
Curry, William T., Jr. .
JOURNAL OF IMMUNOTHERAPY, 2012, 35 (05) :385-389
[2]   Mechanisms of Local Immunoresistance in Glioma [J].
Albesiano, Emilia ;
Han, James E. ;
Lim, Michael .
NEUROSURGERY CLINICS OF NORTH AMERICA, 2010, 21 (01) :17-+
[3]   CT Guidance is Needed to Achieve Reproducible Positioning of the Mouse Head for Repeat Precision Cranial Irradiation [J].
Armour, M. ;
Ford, E. ;
Iordachita, I. ;
Wong, J. .
RADIATION RESEARCH, 2010, 173 (01) :119-123
[4]   Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy [J].
Callahan, Margaret K. ;
Wolchok, Jedd D. ;
Allison, James P. .
SEMINARS IN ONCOLOGY, 2010, 37 (05) :473-484
[5]  
Chi DDJ, 1997, AM J PATHOL, V150, P2143
[6]   Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production [J].
Curran, Michael A. ;
Kim, Myoungjoo ;
Montalvo, Welby ;
Al-Shamkhani, Aymen ;
Allison, James P. .
PLOS ONE, 2011, 6 (04)
[7]   Combining radiotherapy and immunotherapy: A revived partnership [J].
Demaria, S ;
Bhardwaj, N ;
McBride, WH ;
Formenti, SC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03) :655-666
[8]   Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function [J].
Fecci, Peter E. ;
Ochiai, Hidenobu ;
Mitchell, Duane A. ;
Grossi, Peter M. ;
Sweeney, Alison E. ;
Archer, Gary E. ;
Cummings, Thomas ;
Allison, James P. ;
Bigner, Darell D. ;
Sampson, John H. .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :2158-2167
[9]  
Ferrara TA, 2009, CURR OPIN MOL THER, V11, P37
[10]   Systemic effects of local radiotherapy [J].
Formenti, Silvia C. ;
Demaria, Sandra .
LANCET ONCOLOGY, 2009, 10 (07) :718-726